FY2024 EPS Estimate for Sensus Healthcare Boosted by Analyst

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Equities research analysts at Roth Capital increased their FY2024 earnings per share (EPS) estimates for shares of Sensus Healthcare in a research note issued to investors on Thursday, November 14th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per share of $0.40 for the year, up from their prior forecast of $0.36. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.38 per share. Roth Capital also issued estimates for Sensus Healthcare's Q4 2024 earnings at $0.09 EPS, Q1 2025 earnings at $0.16 EPS and Q2 2025 earnings at $0.19 EPS.

A number of other equities analysts also recently issued reports on the company. Maxim Group upped their price target on Sensus Healthcare from $12.00 to $14.00 and gave the company a "buy" rating in a report on Friday. HC Wainwright lifted their price target on shares of Sensus Healthcare from $10.00 to $11.00 and gave the stock a "buy" rating in a research note on Monday.

Sensus Healthcare Trading Up 10.1 %

Shares of SRTS stock traded up $0.77 on Monday, reaching $8.41. 877,143 shares of the stock were exchanged, compared to its average volume of 278,550. Sensus Healthcare has a twelve month low of $2.02 and a twelve month high of $8.69. The company has a market capitalization of $137.83 million, a price-to-earnings ratio of 14.60 and a beta of 1.04. The business's 50 day moving average price is $6.37 and its 200 day moving average price is $5.97.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its holdings in shares of Sensus Healthcare by 34.4% in the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company's stock valued at $2,087,000 after buying an additional 100,294 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Sensus Healthcare by 128.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company's stock valued at $888,000 after purchasing an additional 93,511 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock valued at $849,000 after purchasing an additional 11,525 shares during the period. Sachetta LLC raised its stake in shares of Sensus Healthcare by 12.9% during the second quarter. Sachetta LLC now owns 118,354 shares of the company's stock worth $631,000 after purchasing an additional 13,544 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company's stock worth $412,000 after purchasing an additional 46,732 shares during the period. Hedge funds and other institutional investors own 25.30% of the company's stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.